Media kit

For journalists, advocates, and organizations. Everything here is copyable. Please represent the campaign accurately: we ask for research and review, not for unregulated sales, and we do not provide sourcing or dosing information.

One-paragraph summary

Save SR-17018 is a public-health advocacy campaign asking federal regulators and Congress to study SR-17018 (5,6-dichloro desmethylchlorphine) before placing it into Schedule I on an emergency basis. Many people report it may help reduce opioid withdrawal; those reports are not clinical proof, but the campaign argues they justify urgent, compound-specific research rather than emergency prohibition.

Short campaign blurb

DEA has named SR-17018 in a temporary scheduling notice. The Save SR-17018 campaign asks DEA, FDA/HHS, and Congress to preserve lawful research access, publish compound-specific evidence, and require scientific review before Schedule I placement — not to permit unregulated sales.

The core ask

Delay or narrow the emergency scheduling of SR-17018 specifically.
Separate SR-17018 from other listed compounds and review it on its own merits.
Publish the compound-specific evidence being relied upon.
Preserve lawful research and medical-development access to SR-17018.
Involve HHS/FDA scientific and medical review before any placement.
Avoid blocking potential opioid-withdrawal research before it can be studied.

Key facts & identifiers

Compound	SR-17018 (5,6-dichloro desmethylchlorphine)
CAS	2134602-45-0
Action	Temporary placement in Schedule I (Notice of Intent, 21 U.S.C. 811(h))
Published	July 1, 2026
Federal Register	FR Doc. 2026-13364 (91 FR 39940) verified
DEA docket	DEA-1665 verified
Regulations.gov	DEA-2026-1024 verified

Read the Federal Register notice →

Why this matters

The opioid crisis continues to demand more researched withdrawal-treatment options.
Schedule I placement can chill legitimate scientific research.
Consistent anecdotal reports deserve investigation, not overstatement.
Compound-specific review avoids treating dissimilar substances as identical.

What the campaign is not saying

We are not saying SR-17018 is proven safe or effective.
We are not asking for unregulated sales.
We are not providing sourcing, dosing, or synthesis information.

Suggested media quote

People are reporting that SR-17018 may have unusual potential for reducing opioid withdrawal. Those reports are not clinical proof, but they are strong enough to justify urgent research and compound-specific review. Emergency Schedule I placement could make that research harder before the public-health value is understood.

Anonymized testimonial examples

Examples Illustrative only — not real submissions. Real, moderated stories appear on the stories page.

“After years on opioids, I struggled every time I tried to stop. I believe having researched options for withdrawal could change lives. I want compounds like this studied properly, not shut out before we know.”

— Anonymous — Person with lived experience, Ohio

“I watched someone I love fight to get off opioids. Families like ours need more researched tools, not fewer. I'm asking for careful study, not shortcuts.”

— Anonymous — Family member, Pennsylvania

“I'm not claiming this compound is proven. I'm saying the reports are consistent enough that Schedule I placement before compound-specific research would be a mistake for public health.”

— Anonymous — Clinician, Oregon

For journalists

Questions or interview requests? We aim to respond promptly.

Media contact: press@example.org edit before launch

Email the campaign